Sensydia is a clinical-stage medical technology company in Los Angeles developing the Cardiac Performance System (CPS), a non-invasive platform that measures hemodynamic function — ejection fraction, cardiac output and pulmonary artery pressure — from acoustic and electrical signals analyzed with AI algorithms. CPS is designed to give clinicians rapid hemodynamic assessments in offices, hospitals and clinics without invasive catheterization, to help diagnose and manage heart failure and pulmonary hypertension. The company holds a 2018 FDA 510(k) clearance for a non-invasive ejection-fraction algorithm, has FDA Breakthrough Device designation for CPS, and is completing the ACOUSTIC-1 pivotal study ahead of a planned commercial launch.
1
Round
1
Industry
5
Tags
Oct 13, 2026
Latest raise
Funding activity · 1 round
Oct 13, 2026
$6M
Seed
Led by Colle Capital Partners
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
